why choose us

300×250 Ad Slot

Drug FDA Status

Showing 120 of 172 result(s) (Page 12 of 18)
Drug Name: Duvyzat

Active Ingredient: givinostat

Approval Date: 2024-03-21

Description: To treat Duchenne muscular dystrophy in individuals aged 6 years and older
Press Release
Drug Trials Snapshot

Drug Name: Tryvio

Active Ingredient: aprocitentan

Approval Date: 2024-03-19

Description: To treat hypertension
Drug Trials Snapshot

Drug Name: Rezdiffra

Active Ingredient: resmetirom

Approval Date: 2024-03-14

Description: To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
Press Release
Drug Trials Snapshot

Drug Name: Tevimbra

Active Ingredient: tislelizumab-jsgr

Approval Date: 2024-03-13

Description: To treat unresectable or metastatic esophageal squamous cell carcinoma
Drug Trials Snapshot

Drug Name: Letybo

Active Ingredient: letibotulinumtoxinA-wlbg

Approval Date: 2024-02-29

Description: To temporarily improve the appearance of moderate-to-severe glabellar lines
Drug Trials Snapshot

Drug Name: Exblifep

Active Ingredient: cefepime, enmetazobactam

Approval Date: 2024-02-22

Description: To treat complicated urinary tract infections
Drug Trials Snapshot

Drug Name: Zelsuvmi

Active Ingredient: berdazimer

Approval Date: 2024-01-05

Description: To treat molluscum contagiosum
Drug Trials Snapshot

Drug Name: Wainua

Active Ingredient: eplontersen

Approval Date: 2023-12-21

Description: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Drug Trials Snapshot

Drug Name: Filsuvez

Active Ingredient: birch triterpenes

Approval Date: 2023-12-18

Description: To treat wounds associated with dystrophic and junctional epidermolysis bullosa

Drug Name: Fabhalta

Active Ingredient: iptacopan

Approval Date: 2023-12-05

Description: To treat paroxysmal nocturnal hemoglobinuria

300×250 Ad Slot